CN102159246A - 治疗萎缩性年龄相关黄斑变性的方法 - Google Patents

治疗萎缩性年龄相关黄斑变性的方法 Download PDF

Info

Publication number
CN102159246A
CN102159246A CN2009801368268A CN200980136826A CN102159246A CN 102159246 A CN102159246 A CN 102159246A CN 2009801368268 A CN2009801368268 A CN 2009801368268A CN 200980136826 A CN200980136826 A CN 200980136826A CN 102159246 A CN102159246 A CN 102159246A
Authority
CN
China
Prior art keywords
drug delivery
delivery system
eye
dry amd
bevacizumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801368268A
Other languages
English (en)
Chinese (zh)
Inventor
M·R·罗宾逊
W·M·布兰达
P·M·休斯
J·A·伯克
S·M·惠特卡普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to CN201611271046.2A priority Critical patent/CN107412778A/zh
Publication of CN102159246A publication Critical patent/CN102159246A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2009801368268A 2008-07-18 2009-07-13 治疗萎缩性年龄相关黄斑变性的方法 Pending CN102159246A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611271046.2A CN107412778A (zh) 2008-07-18 2009-07-13 治疗萎缩性年龄相关黄斑变性的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/176,238 US8821870B2 (en) 2008-07-18 2008-07-18 Method for treating atrophic age related macular degeneration
US12/176,238 2008-07-18
PCT/US2009/050373 WO2010009034A2 (en) 2008-07-18 2009-07-13 Method for treating atrophic age related macular degeneration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201611271046.2A Division CN107412778A (zh) 2008-07-18 2009-07-13 治疗萎缩性年龄相关黄斑变性的方法

Publications (1)

Publication Number Publication Date
CN102159246A true CN102159246A (zh) 2011-08-17

Family

ID=41530477

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2009801368268A Pending CN102159246A (zh) 2008-07-18 2009-07-13 治疗萎缩性年龄相关黄斑变性的方法
CN201611271046.2A Pending CN107412778A (zh) 2008-07-18 2009-07-13 治疗萎缩性年龄相关黄斑变性的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201611271046.2A Pending CN107412778A (zh) 2008-07-18 2009-07-13 治疗萎缩性年龄相关黄斑变性的方法

Country Status (11)

Country Link
US (3) US8821870B2 (enExample)
EP (4) EP2664347B1 (enExample)
JP (3) JP2011528656A (enExample)
KR (1) KR20110047196A (enExample)
CN (2) CN102159246A (enExample)
AU (1) AU2009271168B2 (enExample)
BR (1) BRPI0915981A2 (enExample)
CA (1) CA2731270C (enExample)
ES (3) ES2574706T3 (enExample)
RU (3) RU2668371C2 (enExample)
WO (1) WO2010009034A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102988301A (zh) * 2012-12-26 2013-03-27 温州医学院 一种含贝伐单抗的长效缓释微球的制备方法
CN104812397A (zh) * 2012-09-27 2015-07-29 阿勒根公司 用于持续释放蛋白质的生物可降解的药物递送系统
CN108030783A (zh) * 2017-12-27 2018-05-15 广东众生药业股份有限公司 乐伐替尼在制备防治黄斑变性的药物中的用途
CN109073660A (zh) * 2016-02-29 2018-12-21 麦恩泰科特有限公司 可用于治疗湿性年龄相关性黄斑变性的预测性标志物
CN109152769A (zh) * 2016-05-25 2019-01-04 参天制药株式会社 西罗莫司用于治疗伴有持续性水肿的渗出性年龄相关性黄斑变性的用途
CN109966243A (zh) * 2019-05-17 2019-07-05 上海第二工业大学 一种用于眼底黄斑治疗的释药型凝胶及其制备方法
CN116528851A (zh) * 2020-06-26 2023-08-01 普渡研究基金会 用于长期眼部递送的灰黄霉素的药物制剂

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US8197435B2 (en) 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
CN104887389B (zh) 2009-01-29 2017-06-23 弗赛特影像4股份有限公司 后段给药
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
JP2013506693A (ja) * 2009-10-01 2013-02-28 エボニック デグサ コーポレイション 加齢黄斑変性の治療のためのミクロ粒子組成物及び治療法
AU2011206104A1 (en) * 2010-01-14 2012-07-12 Nagoya City University Pharmaceutical for preventing or treating disorders accompanied by ocular angiogenesis and/or elevated ocular vascular permeability
AU2011207301A1 (en) * 2010-01-21 2012-08-09 Allergan, Inc. Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
US20130210876A1 (en) * 2010-01-21 2013-08-15 Allergan, Inc Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
US20110269807A1 (en) 2010-04-30 2011-11-03 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
CA2807554C (en) 2010-08-05 2021-10-26 Forsight Vision4 Inc. Implantable therapeutic device
AU2011285548B2 (en) 2010-08-05 2014-02-06 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
WO2012019136A2 (en) 2010-08-05 2012-02-09 Forsight Vision 4, Inc. Injector apparatus and method for drug delivery
AU2011292160B2 (en) * 2010-08-17 2015-09-03 Ohr Pharmaceutical, Inc. Ophthalmic formulations of squalamine
WO2012051575A2 (en) 2010-10-15 2012-04-19 Iscience Interventional Corporation Device for ocular access
CA2818612C (en) * 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2671589A4 (en) * 2011-02-02 2014-11-19 Public Univ Corp Nagoya City Univ MEDICAMENT FOR PREVENTING OR TREATING DISEASES RELATED TO INTRAOCULAR NEOVASCULARIZATION AND / OR INTRAOCULAR VASCULAR HYPERPERMEABILITY
US8715713B2 (en) 2011-04-29 2014-05-06 Allergan, Inc. Solvent cast film sustained release latanoprost implant
EP2717914B1 (en) * 2011-06-10 2019-10-30 Ramscor, Inc. Sustained release formulations for delivery of proteins to the eye and methods of preparing same
EP2720722A4 (en) 2011-06-16 2014-12-03 Univ Hong Kong Science & Techn MOLECULAR WITH SEVERAL VINYL SULPHONES
EP4249059B1 (en) 2011-06-28 2025-07-30 ForSight Vision4, Inc. An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye
RU2014105495A (ru) * 2011-07-19 2015-08-27 Уилфред ДЖЕФФРИС Способы диагностики и лечения болезни альцгеймера
EP4643921A3 (en) 2011-09-16 2026-01-07 ForSight Vision4, Inc. Fluid exchange apparatus
WO2013074840A1 (en) * 2011-11-15 2013-05-23 Allergan, Inc. Treatment of dry age related macular degeneration
SG11201503637SA (en) 2012-11-08 2015-06-29 Clearside Biomedical Inc Methods and devices for the treatment of ocular diseases in human subjects
EP2968113B8 (en) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
CN104884133B (zh) 2013-03-14 2018-02-23 艾肯运动与健康公司 具有飞轮的力量训练设备
KR102282973B1 (ko) 2013-05-03 2021-07-27 클리어사이드 바이오메디컬, 인코포레이드 안구용 주사를 위한 장치 및 방법
WO2014197317A1 (en) 2013-06-03 2014-12-11 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
EP3016634A2 (en) * 2013-07-05 2016-05-11 Therakine Biodelivery GmbH Drug-delivery composition for topical applications and injections and ophtalmic formulations, method for manufacturing thereof, and methods for delivery a drug-delivery composition
US9782345B2 (en) 2013-10-17 2017-10-10 Jade Therapeutics, Inc. Ocular composition and method
US10568951B2 (en) 2013-11-18 2020-02-25 Formycon Ag Pharmaceutical composition of an anti-VEGF antibody
US9403047B2 (en) 2013-12-26 2016-08-02 Icon Health & Fitness, Inc. Magnetic resistance mechanism in a cable machine
WO2015191445A1 (en) 2014-06-09 2015-12-17 Icon Health & Fitness, Inc. Cable system incorporated into a treadmill
RU2710491C2 (ru) 2014-06-20 2019-12-26 Клиасайд Байомедикал, Инк. Устройство для инъекции лекарственного средства в глазную ткань и способ инъекции лекарственного средства в глазную ткань
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
MX2017001818A (es) 2014-08-08 2017-05-30 Forsight Vision4 Inc Formulaciones estables y solubles de inhibidores de receptor de quinasa tirosina y metodos de preparacion de los mismos.
USD750223S1 (en) 2014-10-14 2016-02-23 Clearside Biomedical, Inc. Medical injector for ocular injection
WO2016135728A1 (en) * 2015-02-26 2016-09-01 Biomas Ltd. Compositions and combinations for the treatment of angiogenesis diseases and disorders
ES2584534B1 (es) * 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
RU2712623C2 (ru) 2015-03-31 2020-01-30 Илдонг Фарм. Ко., Лтд. Фармацевтическая композиция для предотвращения и лечения заболеваний глаз, содержащая в качестве активного ингредиента белок слияния, в котором слиты проникающий в ткань пептид и препарат против фактора роста эндотелия сосудов
EP3305304A4 (en) * 2015-05-29 2019-01-23 Seikagaku Corporation COMPOSITION WITH GLUCOSAMINATE SCANDERIVATE AND CHEMOKIN RECEPTOR ACTIVITY CONTROLLER
US10940360B2 (en) 2015-08-26 2021-03-09 Icon Health & Fitness, Inc. Strength exercise mechanisms
US10953305B2 (en) 2015-08-26 2021-03-23 Icon Health & Fitness, Inc. Strength exercise mechanisms
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
CN108137681B (zh) 2015-09-23 2024-06-18 豪夫迈·罗氏有限公司 抗-vegf抗体的优化的变体
BR112018013407A2 (en) 2015-12-30 2018-12-18 Kodiak Sciences Inc. antibodies and conjugates thereof
IL321994A (en) * 2016-02-08 2025-09-01 Univ Johns Hopkins Bioadhesive-dendrimer polymer hydrogel nanoadhesive and its use
US10390901B2 (en) 2016-02-10 2019-08-27 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
JP6664115B2 (ja) * 2016-03-15 2020-03-13 原　英彰 アフリベルセプトによる網膜保護作用
US10293211B2 (en) 2016-03-18 2019-05-21 Icon Health & Fitness, Inc. Coordinated weight selection
US10441840B2 (en) 2016-03-18 2019-10-15 Icon Health & Fitness, Inc. Collapsible strength exercise machine
WO2017192565A1 (en) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
US10252109B2 (en) 2016-05-13 2019-04-09 Icon Health & Fitness, Inc. Weight platform treadmill
IL264764B2 (en) 2016-08-12 2024-02-01 Clearside Biomedical Inc Devices and methods for adjusting the insertion depth of a drug administration needle
US10661114B2 (en) 2016-11-01 2020-05-26 Icon Health & Fitness, Inc. Body weight lift mechanism on treadmill
US11123411B2 (en) * 2016-12-08 2021-09-21 Gary E. Borodic Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
RU2661621C2 (ru) * 2016-12-19 2018-07-17 Александр Николаевич Епихин Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций
EP3600441A1 (en) 2017-03-22 2020-02-05 Genentech, Inc. Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
CN110913916A (zh) 2017-04-27 2020-03-24 约翰霍普金斯大学 用于血管造影的树状聚合物组合物
WO2018204515A1 (en) 2017-05-02 2018-11-08 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
KR102101969B1 (ko) * 2017-09-06 2020-04-22 (주)인벤티지랩 목시덱틴을 포함하는 마이크로 입자 및 이의 제조 방법
CA3082121C (en) 2017-11-10 2023-01-24 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
BR112020010053A2 (pt) 2017-11-21 2020-11-03 Forsight Vision4, Inc. aparelho para troca de fluido para sistema de liberação de porta expansível e métodos de uso do mesmo
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
SG11202010178XA (en) * 2018-04-17 2020-11-27 Outlook Therapeutics Inc Buffered formulations of bevacizumab for use of treating diseases
KR102192768B1 (ko) * 2018-12-07 2020-12-18 전북대학교산학협력단 식나무 추출물을 포함하는 황반변성의 예방 또는 치료용 약학적 조성물
DE102019112917B4 (de) * 2019-05-16 2021-07-22 Carl Zeiss Meditec Ag Ophthalmologisches Implantat zur Verwendung bei der Behandlung einer Augenkrankheit und Implantationswerkzeug mit einem solchen ophthalmologischen Implantat
KR20250051157A (ko) 2019-06-05 2025-04-16 리제너론 파아마슈티컬스, 인크. 정밀 투여량 전달을 위한 디바이스 및 방법
MX2021016014A (es) * 2019-06-27 2022-04-06 Univ Florida Mejora de la transducción mediada por aav en los tejidos oculares con ácido hialurónico.
GB2601922B (en) 2019-06-27 2024-04-24 Layerbio Inc Ocular device drub delivery systems
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
IL295357B1 (en) 2020-02-06 2025-12-01 Ocular Therapeutix Inc Travoprost sustained-release biodegradable intracameral implants for use in the treatment of ocular diseases
TW202202138A (zh) 2020-03-25 2022-01-16 美商歐克萊製藥公司 含有酪胺酸激酶抑制劑之眼用植入物
EP4277640A4 (en) * 2021-01-12 2024-12-18 The Regents Of The University Of Michigan Treatment and prevention of dry macular degeneration
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
CN120897764A (zh) 2023-04-11 2025-11-04 视尔普斯眼科公司 包含阿西替尼多晶型物iv的眼部植入物

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2446405A (en) 1945-10-31 1948-08-03 Hazeltine Research Inc Tunable ultra high frequency resonator system
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5264188A (en) * 1991-01-22 1993-11-23 Phillips Petroleum Company Multi-stage hydrotreating process and apparatus
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
CA2361615A1 (en) * 1999-02-08 2000-08-10 Human Genome Sciences, Inc. The use of vascular endothelial growth factor 2 antagonist in the treatment of an injury to or disorder of an eye
US7582311B1 (en) * 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
MXPA02002376A (es) * 1999-10-21 2002-08-28 Alcon Universal Ltd Entrega de droga al sub-tenon-.
RU2354398C2 (ru) * 2001-07-13 2009-05-10 Оксиджин, Инк. Композиции и способы введения средств, связывающих тубулин, для лечения глазных заболеваний
US20040229960A1 (en) 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
MXPA05002841A (es) * 2002-09-18 2005-05-27 Oculex Pharm Inc Metodo y aparato de administracion de implantes oculares.
EP1562597A4 (en) * 2002-10-31 2008-05-14 Celgene Corp COMPOSITIONS COMPRISING IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT AND MANAGEMENT OF MACULAR DEGENERATION AND METHODS OF USE THEREOF
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US7589057B2 (en) * 2004-04-30 2009-09-15 Allergan, Inc. Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US20050244472A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US8722097B2 (en) * 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US8591885B2 (en) 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US20070059336A1 (en) 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US7993634B2 (en) * 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
CA2597590A1 (en) * 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
CA2601864A1 (en) * 2005-04-08 2006-10-19 Surmodics, Inc. Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease
HN2006031275A (es) * 2005-09-07 2010-10-29 Amgen Fremont Inc Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
ES2616296T3 (es) * 2005-12-02 2017-06-12 (Osi) Eyetech, Inc. Micropartículas de liberación controlada
WO2007073489A2 (en) * 2005-12-22 2007-06-28 Trustees Of Boston University Molecules for gene delivery and gene therapy, and methods of use thereof
EP1988889A4 (en) * 2006-01-26 2009-07-22 Acucela Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHAMAL DISEASES AND DISORDERS
JP2009535371A (ja) 2006-05-04 2009-10-01 フォベア、ファルマスティカル、ソシエテ、アノニム 血管新生性疾患の治療のための方法
MX2009002054A (es) * 2006-08-31 2009-05-01 Abraxis Bioscience Llc Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis.
WO2008063932A2 (en) 2006-11-10 2008-05-29 Genentech, Inc. Method for treating age-related macular degeneration
EP2102165A2 (en) * 2006-11-24 2009-09-23 AC Immune S.A. N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's
US20080125377A1 (en) * 2006-11-28 2008-05-29 Bartels Stephen P Delivery system for antiangiogenic and antiinflammatory pharmaceuticals and method of use
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US11078262B2 (en) * 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
CA2968112C (en) 2016-05-26 2025-09-23 Op-Hygiene Ip Gmbh MAINTENANCE OF A DISPENSER INTENDED FOR AN INSTALLATION WITH MULTIPLE BATHROOMS
US11210687B2 (en) 2019-05-23 2021-12-28 Capital One Services, Llc Intelligent preprocessing routing to decisioning services

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104812397A (zh) * 2012-09-27 2015-07-29 阿勒根公司 用于持续释放蛋白质的生物可降解的药物递送系统
CN102988301A (zh) * 2012-12-26 2013-03-27 温州医学院 一种含贝伐单抗的长效缓释微球的制备方法
CN109073660A (zh) * 2016-02-29 2018-12-21 麦恩泰科特有限公司 可用于治疗湿性年龄相关性黄斑变性的预测性标志物
CN109073660B (zh) * 2016-02-29 2022-10-28 麦恩泰科特有限公司 可用于治疗湿性年龄相关性黄斑变性的预测性标志物
CN109152769A (zh) * 2016-05-25 2019-01-04 参天制药株式会社 西罗莫司用于治疗伴有持续性水肿的渗出性年龄相关性黄斑变性的用途
US11400080B2 (en) 2016-05-25 2022-08-02 Santen Pharmaceutical Co., Ltd. Use of sirolimus to treat exudative age-related macular degeneration with persistent edema
CN108030783A (zh) * 2017-12-27 2018-05-15 广东众生药业股份有限公司 乐伐替尼在制备防治黄斑变性的药物中的用途
CN109966243A (zh) * 2019-05-17 2019-07-05 上海第二工业大学 一种用于眼底黄斑治疗的释药型凝胶及其制备方法
CN116528851A (zh) * 2020-06-26 2023-08-01 普渡研究基金会 用于长期眼部递送的灰黄霉素的药物制剂

Also Published As

Publication number Publication date
ES2897560T3 (es) 2022-03-01
RU2018133133A (ru) 2020-03-19
CA2731270A1 (en) 2010-01-21
EP2307055A2 (en) 2011-04-13
RU2668371C2 (ru) 2018-09-28
RU2014115647A (ru) 2015-10-27
JP6009511B2 (ja) 2016-10-19
EP2307055B1 (en) 2016-01-06
CN107412778A (zh) 2017-12-01
AU2009271168B2 (en) 2014-08-14
JP2014237713A (ja) 2014-12-18
AU2009271168A1 (en) 2010-01-21
RU2521338C9 (ru) 2014-09-10
EP3524270A1 (en) 2019-08-14
EP2664347A1 (en) 2013-11-20
US20100015158A1 (en) 2010-01-21
US10363214B2 (en) 2019-07-30
EP2664347B1 (en) 2019-03-13
RU2011105409A (ru) 2012-08-27
JP2016169233A (ja) 2016-09-23
US20140322206A1 (en) 2014-10-30
CA2731270C (en) 2017-05-30
EP3950002A1 (en) 2022-02-09
KR20110047196A (ko) 2011-05-06
JP6132964B2 (ja) 2017-05-24
EP3524270B1 (en) 2021-09-15
US8821870B2 (en) 2014-09-02
ES2574706T3 (es) 2016-06-21
BRPI0915981A2 (pt) 2020-08-18
US20190336441A1 (en) 2019-11-07
ES2720882T3 (es) 2019-07-25
WO2010009034A2 (en) 2010-01-21
WO2010009034A3 (en) 2010-05-06
RU2521338C2 (ru) 2014-06-27
JP2011528656A (ja) 2011-11-24

Similar Documents

Publication Publication Date Title
JP6132964B2 (ja) 萎縮性加齢性黄斑変性の処置方法
TWI481423B (zh) 眼內藥物輸送系統
US20100247606A1 (en) Intraocular sustained release drug delivery systems and methods for treating ocular conditions
US20090148527A1 (en) Intraocular formulation
HK40012677A (en) Treating atrophic age related macular degeneration
HK1190092A (en) Bevacizumab for use in a method for treating atrophic age related macular degeneration
AU2014202336A1 (en) Intraocular drug delivery systems
HK1190092B (en) Bevacizumab for use in a method for treating atrophic age related macular degeneration

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110817